Format

Send to

Choose Destination
Clin Pharmacol Ther. 2016 Jan;99(1):36-7. doi: 10.1002/cpt.161. Epub 2015 Jul 16.

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update.

Author information

1
Division of Medicinal Safety Science, National Institute of Health Sciences, Kamiyoga, Setagaya, Tokyo, Japan.
2
Department of Medicine, University of Otago, Christchurch, New Zealand.
3
Department of Pharmaceutical Sciences, St. Jude Children's Research Hospital, Memphis, Tennessee, USA.
4
Departments of Medicine and Biochemistry, Duke University School of Medicine, Durham, North Carolina, USA.
5
Department of Genetics, Stanford University Medical Center, Stanford, California, USA.
6
ACOS for Research, Department of Veterans Affairs Medical Center, Indianapolis, Indiana, USA.
7
Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
8
Department of Pharmacology/Toxicology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
9
Department of Pharmacology, Research and Diagnostic Center for Emerging Infectious Diseases, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.
10
Laboratory for Pharmacogenetics, RIKEN, Center for Genomic Medicine, Yokohama, Japan.
11
Institute of Data Analysis, StaGen, Tokyo, Japan.
12
Pharmacy Department, National Institutes of Health Clinical Center, Bethesda, Maryland, USA.
13
Division of Infectious Diseases, Institute of Immunology and Infectious Disease, Murdoch University, Murdoch, Western Australia.
14
Division of Infectious Diseases, Vanderbilt University Medical Center, Nashville, Tennessee, USA.
15
Laboratory for International Alliance on Genomic Research, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan.
16
National Center for Genome Medicine, Institute of Biomedical Sciences, Academia Sinica, Taipei, Taiwan.
17
School of Chinese Medicine, China Medical University, Taichung, Taiwan.

Abstract

The Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for HLA-B*58:01 Genotype and Allopurinol Dosing was originally published in February 2013. We reviewed the recent literature and concluded that none of the evidence would change the therapeutic recommendations in the original guideline; therefore, the original publication remains clinically current. However, we have updated the Supplemental Material and included additional resources for applying CPIC guidelines into the electronic health record. Up-to-date information can be found at PharmGKB (http://www.pharmgkb.org).

PMID:
26094938
PMCID:
PMC4675696
DOI:
10.1002/cpt.161
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center